Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Taxes

Summary of Significant components of the Company’s deferred tax assets

	December 31,
	2019		2018
Deferred tax assets
Net operating loss carryforwards	$	32,704	$	26,993
Research and development credits		853		701
Depreciation and amortization		578		825
Accrued LifeCell settlement		—		252
Accrued expenses and other		259		191
Inventory reserve		417		425
Gross deferred tax asset		34,811		29,387
Valuation allowance		(34,811)		(29,387)
Net deferred tax asset	$	—	$	—

Schedule of Company’s net operating loss (NOL) carryforwards

	December 31,
	2019		2018
NOL carryforwards
Federal	$	122,925	$	99,939
State		106,062		91,797

Schedule of reconciliation of income tax benefit

	Year ended December 31,
	2019		2018		2017
Rate reconciliation
Federal tax benefit at statutory rate	(21.0)	%	(21.0)	%	(34.0)	%
State rate, net of federal benefit	(2.9)		(4.7)		(5.2)
Permanent differences	0.4		0.5		5.5
Change in federal rate	—		—		48.0
Research and development	(0.7)		(0.8)		—
Change in valuation allowance	24.2		26.3		(15.1)
Other	—		(0.3)		0.8
Total tax provision	—	%	—	%	—	%